跳至主要内容
临床试验/NCT01660204
NCT01660204已完成不适用

Antibiotic Treatment of Community-acquired Pneumonia: a Prospective Comparison of Dutch Guideline Advices.

UMC Utrecht7 个研究点 分布在 1 个国家目标入组 2,283 人开始时间: 2011年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
UMC Utrecht
入组人数
2,283
试验地点
7
主要终点
Day 90 Mortality

研究概览

简要总结

The purpose of this study is to compare the cost(effectiveness) of three existing antibiotic strategies for patients with community-acquired pneumonia admitted to the hospital, but not the ICU.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •All patients admitted to one of the participating hospitals needing treatment for CAP, not being admitted to the ICU are eligible for study inclusion.
  • •Admission is defined as hospital stay for more than 24 hours.

排除标准

  • •Patients who are readmitted with CAP within 2 weeks after a previous episode are not eligible.
  • •Patients with cystic fibrosis are not eligible.

研究组 & 干预措施

Betalactam monotherapy

Active Comparator

Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone

干预措施: Preferred empirical treatment (Other)

Betalactam combination with macrolide

Active Comparator

Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin

干预措施: Preferred empirical treatment (Other)

Quinolone monotherapy

Active Comparator

Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin

干预措施: Preferred empirical treatment (Other)

结局指标

主要结局

Day 90 Mortality

时间窗: 90 days from admission

We will assess all-cause mortality on day 90 from admission from the municipal personal records database

次要结局

  • Length of intravenous antibiotic treatment(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Length of hospital stay(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Tolerability(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Complications(Participants will be followed for the duration of hospital stay, an expected average of 1 week)
  • Health care costs and non-health care costs(28 days from admission)

研究者

发起方
UMC Utrecht
申办方类型
Other
责任方
Principal Investigator
主要研究者

MJM Bonten

Professor

UMC Utrecht

研究点 (7)

Loading locations...

相似试验